Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .
Do social functioning and symptoms improve with continuation antidepressant treatment of persistent depressive disorder? An observational study.
OBJECTIVE To determine efficacy of continued treatment with the serotonin norepinephrine reuptake inhibitor duloxetine on symptom reduction and functional improvement in out patients with dysthymia . METHOD Fifty out patients with DSM-IV-TR diagnosed dysthymia who had participated in a 10 week double-blind , placebo-controlled study of duloxetine received open treatment for three months . Nineteen duloxetine responders continued duloxetine , 24 patients initially treated with placebo started open duloxetine treatment , and 7 duloxetine non-responders were treated with desvenlafaxine or bupropion , selected by clinician choice . RESULTS Patients continuing duloxetine maintained symptom improvement , 84 % meeting response and 63 % remission criteria at week 22 . Patients initially treated with placebo showed similarly high levels of response ( 83 % ) and remission ( 62 % ) at week 22 , and most duloxetine non-responders subsequently responded to other antidepressants . Duloxetine-continuation patients improved modestly between weeks 10 and 22 on measures of social and cognitive functioning and temperament . Despite this improvement concurrently across several functional domains , 66.7 % of patients continuing duloxetine remained in the impaired range of functioning according to the Social Adjustment Scale ( SAS ) . CONCLUSIONS Continued duloxetine treatment appears to be effective in maintaining symptom response in dysthymic disorder , and has positive effects on social functioning . However , the majority of patients do not show normalization of functioning , even when controlling for remission status . Additional treatments should be considered to target residual impairments in social functioning in mood remitted patients with persistent depressive disorder
Results : Duloxetine may be an effective treatment for mood spectrum disorders , panic disorder , several symptom clusters of borderline personality , and as add-on drug in schizophrenia .
Modest or conflicting results have been found for the efficacy of duloxetine in obsessive-compulsive disorder , posttraumatic stress disorder , eating , and sexual disorders .
Background : Duloxetine hydrochloride ( DUL ) is an antidepressant included in the pharmacological class of serotonin-norepinephrine reuptake inhibitors approved for the treatment of major depressive disorder , generalized anxiety disorder , diabetic peripheral neuropathic pain , fibromyalgia , and chronic musculoskeletal pain .
The aim of this review was to eluci date current evidence s on the use of DUL in the treatment of a variety of psychiatric disorders .